Inhibikase Therapeutics Q3 2026 Results: Net Loss of $20.5M, Loss Widens
Inhibikase Therapeutics reported a significant increase in total assets to $201.8 million as of September 30, 2026, driven by a substantial rise in marketable securities. The company's accumulated deficit grew to $199.1 million, reflecting ongoing research and development investments, while common stock outstanding increased to 140,269,633 shares.
- Key figure
- Net loss $20.5M